



Pardes Biosciences to Host Virtual Investor Event

February 9, 2022

Company to host conference call and webcast at 3 p.m. PT on Tuesday, February 15, 2022

CARLSBAD, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19), today announced that a virtual investor event will be hosted by the company's management team following the presentation of clinical data from the ongoing PBI-0451 Phase 1 trial at the 29th Conference On Retroviruses And Opportunistic Infections (CROI) 2022. The conference call and webcast will take place on Tuesday, February 15 at 3:00 p.m. PT / 6:00 p.m. ET.

Individuals interested in listening to the event may do so by dialing (855) 427-5533 for domestic callers, or (409) 220-9396 for international callers and reference conference ID: 5686644; or from the webcast link in the investors section of the company's website at: www.pardesbio.com. The webcast will be available in the investors section on the company's website for 30 days following the completion of the call.

The event will follow Pardes' late-breaking poster presentation "PBI-0451 an orally administered 3CL protease inhibitor of SARS-CoV-2 for COVID-19," taking place Tuesday, February 15, 2022, 1:00 – 2:30 p.m. PT at the CROI 2022 virtual conference. Additional information on the conference can be found at www.croiconference.org.

About Pardes Biosciences, Inc.

Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company's lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections and associated diseases (i.e. COVID-19), the virus responsible for COVID-19. For more information, please visit www.pardesbio.com.

About PBI-0451

PBI-0451 is an investigational orally bioavailable direct-acting antiviral (DAA) inhibitor of the main protease (Mpro), an essential protein required for the replication of coronaviruses, including the novel SARS-CoV-2 that causes COVID-19. This protease is highly similar across all coronaviruses, including known and emerging coronavirus variants. PBI-0451 is being developed for the treatment and prevention of SARS-CoV-2 infection and associated diseases. PBI-0451 is currently in a Phase 1 placebo-controlled, blinded, randomized, dose escalation study in healthy volunteers in New Zealand evaluating the safety, tolerability, and pharmacokinetics of PBI-0451 after single and multiple ascending doses. For more information, please visit www.pardesbio.com.

Availability of Other Information about Pardes Biosciences

Pardes intends to use the Investors page of its website (<https://ir.pardesbio.com>) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD (Fair Disclosure). Accordingly, investors should monitor Pardes' Investors website, in addition to following Pardes' press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

Investor Contact:

ir@pardesbio.com

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com